Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Makes Tocilizumab Launch Prediction As Biosimilars Progress

One Analyst Suggests: ‘There Have Been Filings’

Executive Summary

Roche gave small insight into its expectations around biosimilar competition for its Actemra/RoActemra (tocilizumab) treatment for inflammatory diseases. Extraordinary demand for the biologic led sales to skyrocket by 143% in the third quarter and caused supply constraints for the originator.

You may also be interested in...



Celltrion Gets Ready To Push Tocilizumab Into Phase III

Celltrion has provided the latest update on progress for its CT-P47 proposed tocilizumab biosimilar, with Phase III trials set to begin for its rival to Actemra/RoActemra.

Biogen and Bio-Thera Report Progress On Tocilizumab

Biogen and Bio-Thera have revealed positive Phase III data for their proposed tocilizumab biosimilar rival to Actemra/RoAcetmra.

Theramex And Enzene Continue Alliance With Deal For RoActemra Rival

Theramex and Enzene have struck a deal to commercialize a tocilizumab biosimilar rival to Roche’s RoActemra in Europe – including the UK and Switzerland – as well as Australia. The two companies recently partnered for Enzene’s proposed biosimilar version of Prolia (denosumab).

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel